Marshall Wace, LLP G1 Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.12 - $3.73 $175,207 - $583,502	-156,435 Reduced 30.27%	360,293 $1.1 Million
Q3 2023 Nov 14, 2023	BUY	$1.22 - $2.67 $562,576 - $1.23 Million	461,128 Added 829.37%	516,728 $744,000
Q2 2023 Aug 14, 2023	SELL	$2.46 - $3.14 $1.74 Million - $2.22 Million	-707,776 Reduced 92.72%	55,600 $138,000
Q1 2023 May 15, 2023	SELL	$2.57 - $8.16 $595,242 - $1.89 Million	-231,612 Reduced 23.28%	763,376 $2.05 Million
Q4 2022 Feb 14, 2023	BUY	$5.19 - $13.5 $1.88 Million - $4.9 Million	362,810 Added 57.39%	994,988 $5.4 Million
Q3 2022 Nov 14, 2022	BUY	$5.17 - $16.99 $803,190 - $2.64 Million	155,356 Added 32.58%	632,178 $7.9 Million
Q2 2022 Aug 15, 2022	BUY	$4.04 - $8.51 $1.53 Million - $3.22 Million	377,801 Added 381.54%	476,822 $2.36 Million
Q1 2022 May 16, 2022	BUY	$7.6 - $11.02 $752,559 - $1.09 Million	99,021 New	99,021 $753,000
Q1 2020 May 15, 2020	SELL	$9.07 - $26.32 $162,752 - $472,286	-17,944 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$20.54 - $31.0 $368,569 - $556,264	17,944 New	17,944 $474,000
Q3 2019 Nov 14, 2019	SELL	$22.78 - $40.58 $4.32 Million - $7.69 Million	-189,486 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$16.03 - $31.1 $1.68 Million - $3.25 Million	104,562 Added 123.12%	189,486 $5.81 Million
Q1 2019 May 14, 2019	SELL	$14.4 - $21.45 $4.34 Million - $6.47 Million	-301,586 Reduced 78.03%	84,924 $1.41 Million
Q4 2018 Feb 14, 2019	BUY	$16.51 - $51.33 $5.66 Million - $17.6 Million	342,990 Added 788.12%	386,510 $7.4 Million
Q3 2018 Nov 14, 2018	BUY	$43.15 - $67.97 $1.88 Million - $2.96 Million	43,520 New	43,520 $2.28 Million

Others Institutions Holding GTHX

# of Institutions

Shares Held

3.55M

Call Options Held

11.7K

Put Options Held

View Full List

About G1 Therapeutics, Inc.

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

More about GTHX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account